PRESS RELEASE published on 09/21/2026 at 19:00, 1 month 20 days ago Inside Information / Other news releases MaaT Pharma announces Pre-IND meeting with FDA for MaaT034 clinical development in solid tumors. Company advances microbiome therapies for cancer patients through immune modulation FDA MaaT Pharma Pre-IND Meeting MaaT034 Microbiome Therapies
BRIEF published on 09/18/2026 at 07:35, 1 month 23 days ago MaaT Pharma fait face à un revers suite à la décision du CHMP concernant MaaT013 Essai Clinique MaaT013 Décision Du CHMP Étude PHOENIX Plan Réglementaire
BRIEF published on 09/18/2026 at 07:35, 1 month 23 days ago MaaT Pharma Faces Setback with CHMP Decision on MaaT013 Clinical Trial MaaT013 CHMP Decision PHOENIX Study Regulatory Plan
PRESS RELEASE published on 09/18/2026 at 07:30, 1 month 23 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce l'opinion négative du CHMP sur MaaT013 (Xervyteg®) et le plan de développement de l'essai clinique PHOENIX aux États-Unis et en Europe Phoenix Essai Clinique MaaT Pharma CHMP MaaT013
PRESS RELEASE published on 09/18/2026 at 07:30, 1 month 23 days ago Inside Information / Other news releases MaaT Pharma provides update on CHMP negative opinion for MaaT013 (Xervyteg) development plan, focusing on Phase 3 trial PHOENIX. FDA support noted for potential patient enrollment in H1 2027 FDA Phase 3 Trial MaaT Pharma CHMP MaaT013
BRIEF published on 09/15/2026 at 07:35, 1 month 26 days ago MaaT Pharma : vote défavorable du CHMP pour MaaT013 MaaT Pharma CHMP MaaT013 Essai Randomisé Vote Négatif
BRIEF published on 09/15/2026 at 07:35, 1 month 26 days ago MaaT Pharma: unfavorable vote by the CHMP for MaaT013 MaaT Pharma MaaT013 CHAMP Negative Vote Randomized Trial
PRESS RELEASE published on 09/15/2026 at 07:30, 1 month 26 days ago Inside Information / Other news releases MaaT Pharma receives negative CHMP trend vote for MaaT013 (Xervyteg) conditional marketing authorization application in Europe. Company vows to explore options for patient access MaaT Pharma CHMP Clinical Benefit Xervyteg Negative Trend
PRESS RELEASE published on 09/15/2026 at 07:30, 1 month 26 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce une tendance négative du CHMP pour MaaT013 (Xervyteg®) en Europe. Retour oral révéle préoccupations sur bénéfice clinique et sécurité MaaT Pharma CHMP MaaT013 Xervyteg® Tendance Négative
BRIEF published on 07/24/2026 at 12:17, 3 months 18 days ago Invus Public Equities réduit sa participation dans MAAT PHARMA Droits De Vote Franchissement De Seuil Cession D'actions MaaT Pharma Invus
Published on 11/12/2026 at 01:40, 3 hours 13 minutes ago Nexteer Announces First Share Repurchase Programme of Up to US$60 Million
Published on 11/11/2026 at 23:30, 5 hours 23 minutes ago Faraday Copper Reports Third Quarter 2026 Financial Results and Announces Changes to the Board of Directors
Published on 11/11/2026 at 23:05, 5 hours 48 minutes ago Vox Royalty Reports Q3 2026 Results and Declares Quarterly Dividend
Published on 11/11/2026 at 23:00, 5 hours 53 minutes ago CCL Industries Announces Appointment of New Director
Published on 11/11/2026 at 22:30, 6 hours 23 minutes ago 55 North Gold Qualifies for Trading on the OTCQB Venture Market and Launches New Corporate Website
Published on 11/12/2026 at 02:20, 2 hours 33 minutes ago Nanjing Offers a Window into the Yangtze River's Cultural Heritage and Renewal
Published on 11/11/2026 at 19:29, 9 hours 24 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 10 hours 12 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 10 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 11 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 11 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 11 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
